Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | VHL | P40337 | 1/20 | 0.39 |
| ▸ | ELOC | Q15369 | 1/20 | 0.39 |
| ▸ | ELOB | Q15370 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18162627 | 0.81 | NOTUM (0.48) | NOTUMKDM4EHTTS100A4ALDH1A1 | |
| SCHEMBL24188888 | 0.79 | ALDH1A1 (0.44) | NOTUMVHLELOCELOBKDM4E | |
| SCHEMBL5635241 | 0.78 | MEN1 (0.47) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL10464 | 0.78 | MAPT (0.46) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL7502 | 0.78 | PARP10 (0.39) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL8473139 | 0.74 | KDM4E (0.36) | VHLELOCELOBKDM4EHTT | |
| SCHEMBL7101648 | 0.74 | MAPT (0.50) | S100A4ALDH1A1CA2MAPTCA9 | |
| SCHEMBL7325775 | 0.74 | ALDH1A1 (0.41) | VHLELOCELOBKDM4EALDH1A1 | |
| SCHEMBL14053008 | 0.73 | VHL (0.37) | NOTUMVHLELOCELOBKDM4E | |
| SCHEMBL21189321 | 0.73 | VHL (0.38) | VHLELOCELOBKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744651-A2 | A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS | iOnctura SA (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4727554-A1 | COMBINATIONS OF IOA-244, A PD-1 OR PD-L1 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT TO TREAT CANCER | iOnctura SA (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12605389-B2 | PI3K-δ inhibitor for use in treatment regimens | IONCTURA SA (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-4676478-A1 | COMBINATION OF ROGINOLISIB AND BCL-2 INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | iOnctura SA (CH) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676454-A1 | COMBINATION OF ROGINOLISIB AND HDAC INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | iOnctura SA (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-115836077-B | Oxazaspiro derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025073968-A1 | COMBINATION OF ROGINOLISIB WITH A MALT1-GLS INHIBITOR | IONCTURA SA (CH) | 2025-04-10 | — | — | WO | disclosed |
| EP-4313058-B1 | COMPOSITION COMPRISING ROGINOLISIB AND DOSAGE REGIME FOR TREATING CANCER OR AN INFLAMMATORY OR AUTOIMMUNE DISEASE | IONCTURA SA (CH) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024256552-A1 | COMBINATIONS OF IOA-244, A PD-1 OR PD-L1 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT TO TREAT CANCER | IONCTURA SA (CH) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024184233-A1 | COMBINATION OF ROGINOLISIB AND BCL-2 INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | IONCTURA SA (CH) | 2024-09-12 | — | — | WO | disclosed |
| EP-1562944-A1 | PYRAZOLOQUINOLINES WITH IMMUNOMODULATING ACTIVITY | Active Biotech AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| US-20040116461-A1 | Immunomodulatory compounds | ACTIVE BIOTECH AB (SE) | 2004-06-17 | — | — | US | disclosed |
| WO-2004048378-A1 | PYRAZOLOQUINOLINES WITH IMMUNOMODULATING ACTIVITY | ACTIVE BIOTECH AB (SE) | 2004-06-10 | — | — | WO | disclosed |
| EP-0212428-B1 | DIHYDROBENZO/B /THIOPHENES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS ANTIFUNGALS | SCHERING CORPORATION (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4731364-A | Dihydrobenzo(B)thiophenes and pharmaceutical compositions thereof useful as antifungals | SCHERING CORPORATION (US) | 1988-03-15 | — | — | US | disclosed |
| EP-0212428-A1 | Dihydrobenzo/b /thiophenes and pharmaceutical compositions thereof useful as antifungals | SCHERING CORPORATION (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0054233-B1 | NOVEL BENZO(B)THIOPHENES, BENZO(B)FURANS, THIOCHROMANS AND CHROMANS, PROCESSES FOR THEIR PREPARATION AND ANTIMICROBIAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-09-24 | — | — | EP | disclosed |
| US-4468404-A | MICROBIOCIDES | SCHERING CORPORATION (US) | 1984-08-28 | — | — | US | disclosed |
| US-4352808-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SCHERING CORPORATION (US) | 1982-10-05 | — | — | US | disclosed |
| EP-0054233-A1 | Novel benzo(b)thiophenes, benzo(b)furans, thiochromans and chromans, processes for their preparation and antimicrobial compositions containing them | SCHERING CORPORATION (US) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605389-B2 | PI3K-δ inhibitor for use in treatment regimens | PIK3CD, PIK3R5, PIK3R4 | NOTUM 4238/4885VHL 2547/4885ELOC 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.